Research Reports

Summary

McKesson Corporation's subsidiary entered into a $2.0 billion senior secured credit facility on April 1, 2026, comprising $750 million and $250 million term loans maturing in 2031 and 2028 respectively, and a $1.0 billion revolving facility maturing in 2031, with SOFR- and Base Rate-based interest pricing and financial covenants.

Key takeaways

McKesson Medical-Surgical Top Holdings Inc. entered a $2.0 billion Senior Secured Credit Facility on April 1, 2026, including $750M Term Loan A-1 (due 2031), $250M Term Loan A-2 (due 2028), and $1.0B Revolving Credit Facility (due 2031).

Initial interest rates are set at Adjusted Term SOFR + 1.250% for Term Loan A Facilities and Term Benchmark Rate + 1.250% or Base Rate + 0.250% for the Revolving Facility, subject to future adjustments based on leverage ratios and credit ratings.

The facilities are secured by substantially all tangible and intangible assets of the Borrower and certain U.S. subsidiaries, subject to defined exceptions and excluded assets.

The Credit Agreement includes quarterly financial maintenance covenants: a maximum Total Net Leverage Ratio and a minimum Interest Coverage Ratio, alongside customary negative covenants restricting indebtedness, liens, investments, dispositions, and dividends.

JPMorgan Chase Bank, N.A. serves as Administrative Agent and Collateral Agent; Bank of America, Citigroup, Goldman Sachs, and Wells Fargo Securities are Joint Lead Arrangers and Bookrunners.

Full analysis

This $2.0 billion senior secured credit facility represents a strategic refinancing and liquidity enhancement for McKesson’s medical-surgical distribution business, structured across three tranches with staggered maturities to optimize debt service timing and flexibility. The Term Loan A-1 ($750M, 2031) and Term Loan A-2 ($250M, 2028) provide committed long-term capital, while the $1.0 billion revolving facility offers ongoing working capital support through 2031. The interest rate structure—anchored to SOFR and Base Rate with margins tied to leverage and credit ratings—introduces performance-based pricing that incentivizes disciplined balance sheet management. The inclusion of quarterly financial covenants (Total Net Leverage Ratio and Interest Coverage Ratio) signals lender expectations for continued earnings stability and cash flow generation from the subsidiary’s operations. Security extends broadly across the Borrower’s and key U.S. subsidiaries’ assets, reflecting the lenders’ reliance on enterprise-level collateral coverage rather than narrow asset pledges. Joint lead arrangers include five major global banks, underscoring broad market confidence and syndication depth. For investors, this facility strengthens near- to medium-term liquidity, supports strategic initiatives within McKesson’s medical-surgical segment, and introduces transparent, rating-sensitive cost-of-capital discipline—though it also adds a layer of covenant compliance risk requiring ongoing monitoring of leverage and coverage metrics.